RxDoctor Payments DataLook up a doctor →

Nouman Asif, MD

Hematology & Oncology · Rehoboth Beach, DENPI 1790947174

Payments from drug & device makers

$7,555in general payments, 2019–2025

Across 347 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$958
  • AstraZeneca$679
  • Novartis$486
  • E.r. Squibb & Sons, L.L.C.$428
  • GSK$390
  • AVEO Pharmaceuticals, Inc.$354
  • plus $4K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)36$958
AstraZeneca(2 entities)31$679
Novartis24$486
E.r. Squibb & Sons, L.L.C.27$428
GSK14$390
AVEO Pharmaceuticals, Inc.6$354
Sanofi17$329
AbbVie14$321
Genentech USA, Inc.17$311
Amgen13$289
Pharmacyclics LLC, An Abbvie Company11$250
Pfizer12$231
Daiichi Sankyo Inc.10$221
EMD Serono, Inc.6$177
Merck8$170
Exelixis Inc.6$154
Eisai Inc.7$133
Incyte Corporation5$104
Bayer5$102
Takeda Pharmaceuticals U.S.A., Inc.5$91
Array Biopharma Inc4$84
Bristol Myers Squibb4$73
Taiho Oncology, Inc.4$70
Lilly USA, LLC4$68
Beigene USA, Inc.3$67
Gilead3$62
Rigel Pharmaceuticals, Inc.3$54
Regeneron Healthcare Solutions, Inc.2$52
Tactile Systems Technology Inc3$42
Tersera Therapeutics LLC2$42
Springworks Therapeutics, Inc.2$38
Seagen Inc.2$36
Mirati Therapeutics, Inc.2$35
Deciphera Pharmaceuticals Inc.2$35
Ipsen Biopharmaceuticals, Inc2$35
Tesaro, Inc.2$34
Astellas Pharma US Inc2$32
Karyopharm Therapeutics Inc.1$31
Pharmaessentia USA Corporation1$31
Puma Biotechnology, Inc.2$30
Foundation Medicine, Inc.2$29
Geron Corporation1$29
AMAG Pharmaceuticals, Inc.2$28
Agios Pharmaceuticals, Inc.2$27
Pharmacosmos Therapeutics Inc.1$25
Global Blood Therapeutics, Inc.1$24
Fresenius Kabi USA, LLC1$24
Sobi, Inc1$23
Myovant Sciences Inc.1$22
Sanofi-aventis U.S. LLC1$21
Verastem, Inc.1$21
Legend Biotech USA Inc.1$21
EUSA Pharma (US) LLC1$20
ADC Therapeutics America, Inc.1$19
Boston Scientific1$19
Shire North American Group Inc1$17
Dova Pharmaceuticals1$16
Angiodynamics, Inc.1$16
Acrotech Biopharma Inc.1$15
Clovis Oncology, Inc.1$8

How this compares

$7,555 in reported general payments places this provider in the 80th percentile of 26 hematology & oncology providers in Delaware.

See all hematology & oncology providers in Delaware →

Medicare billing

Part B allowed, 2024
$6,869,608
Medicare patients
967
Services billed
274,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Rehoboth Beach

See the full list for Delaware →

Where these figures come from

Is this you, or does something look wrong? →